AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop transformational gene therapies for patients with rare and debilitating diseases. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by single gene mutations, that significantly affect visual function. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
For more information on AGTC and our clinical trials please visit www.AGTC.com
For more information on Paul Castle, visit the Foundation Fighting Blindness’ Beacon Stories: https://www.fightingblindness.org/resources/legally-blind-artist-paul-castle-expresses-his-story-through-art-66
